California Institute for Regenerative Medicine (CIRM) has awarded a $5.8 million translational research grant to a scientist at the University of California, Los Angeles (UCLA) to further support the ...

What is Cushing's syndrome? Cushing's syndrome is a hormonal disorder. It’s caused when you have high levels of the hormone cortisol over a long time. Cushing's syndrome is fairly rare. It most often ...

Scientists from Delft, Vienna, and Lausanne discovered that the protein machines that shape our DNA can switch direction ... such as Cornelia de Lange syndrome, linked to SMCs, where the motors ...

Nonsyndromic means that the condition is not part of another syndrome. Research has shown that duplications or deletions of genomic DNA in regions that regulate cardiac development contribute to ...

The Chicago Cubs appear poised to challenge for the top spot in the National League Central and reportedly are interested in signing a 33-save hurler before winter's end. Drew VonScio of Newsweek ...

today announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for ...

That partner, Japan’s Nippon Shinyaku, is handing over $110 million upfront to lead on the commercialization of two gene therapies—RGX-121 for Hunter syndrome and RGX-111 for Hurler syndrome.

The Milwaukee Brewers shouldn't be done adding yet. There's still roughly a month until pitchers and catchers report to Spring Training and too many solid players still out there in free agency to ...

The partnership will focus on advancing RGX-121 as a treatment for mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for treating mucopolysaccharidosis I (MPS I), also ...

The other treatment, RGX-111, treats another type of mucopolysaccharidosis called Hurler syndrome. It’s earlier in clinical testing. Regenxbio will lead future clinical development of both RGX-121 and ...